August 24, 2024
Managing Metabolic Disorders Pharmacy CE Conference
Saturday, August 24, 2024
Beyond Insulin: Advancements in Type 1 Diabetes Care
8:00-9:30am Consultant/General
Jasmine B. R. Cutler, Pharm.D., CPh, Assistant Professor, Dept of Pharmacotherapeutics and Clinical Research, USF Health Taneja College of Pharmacy, University of South Florida
Upon completion of this activity, pharmacists will be able to: Discuss the pathophysiology, clinical presentation, and risk factors of diabetes; Explain the differences between Type 1 and Type 2 diabetes; Discuss available treatment options for Type 1 diabetes; Demonstrate proper insulin administration; Discuss blood glucose monitoring and management of hypoglycemia and hyperglycemia; Introduce emerging therapies and technologies used in the treatment of diabetes, specifically Type 1 diabetes; Discuss the financial implications of Type 1 diabetes and available resources to address patient concerns and questions; Highlight lifestyle management of Type 1 diabetes; Apply learned concepts about Type 1 diabetes to a patient case.
UAN: 0675-0000-24-021-L01-P*
Rethinking and Reframing Obesity Management
9:30-11:00am Consultant/General
Marile Santamarina, PharmD, CPh, CDE, CPT, Sr. Medical Science Liaison, Immunology, Fresenius Kabi USA
Upon completion of this activity, pharmacists will be able to: Identify obesity as a chronic disease; Review the challenges of anti-obesity drug development; Discuss clinical practice guidelines for the management of obesity.
UAN: 0675-0000-24-022-L01-P
A New Era in the Management of Type 2 Diabetes
11:15-12:45pm Consultant/General
Marile Santamarina, PharmD, CPh, CDE, CPT, Sr. Medical Science Liaison, Immunology, Fresenius Kabi USA
Upon completion of this activity, pharmacists will be able to: Provide an overview of complex pathophysiology of Type 2 Diabetes (T2D); Review change progression in the American Diabetes Association Clinical Practice Guidelines from 2018 through 2024; Discuss the clinical positioning of newer drug classes in the management of type 2 diabetes; Recommendation clinical decisions using patient practice cases.
UAN: 0675-0000-24-023-L01-P
Critical Importance of Lowering LDL-C and Applying Lipid Guidelines
12:45-2:15pm Consultant/General
Ana M. Alvarez, PharmD, CPh, LCC, Senior Medical Science Liaison, Cardiovascular, Novo Nordisk, Inc
Upon completion of this activity, pharmacists will be able to: Correlate the relationship between plasma lipids and coronary heart disease; Defend the rationale for drug selection among various classes of drugs used to reduce cholesterol; Integrate guideline-recommended strategies for lowering LDL-C in primary and secondary prevention of atherosclerotic cardiovascular disease (ASCVD); Develop evidence-based treatment plan for patients with elevated LDL-C.
UAN: 0675-0000-24-024-L01-P*
No Comments